A Double Blind, Placebo-Controlled, Phase 2 Study to Assess the Safety, Tolerability and Efficacy of ISIS 449884 Administered Once Weekly to Patients With Type 2 Diabetes Mellitus Being Treated With Metformin
Phase of Trial: Phase II
Latest Information Update: 07 Jul 2016
At a glance
- Drugs IONIS-GCGRRx (Primary) ; Metformin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Ionis Pharmaceuticals; Isis Pharmaceuticals
- 24 Jan 2015 Planned number of patients changed from 72 to 77.
- 24 Nov 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 16 Jun 2014 According to the Isis media release, results from this trial presented at the American Diabetes Association 74th Scientific Sessions.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History